Clinical Effect of Linagliptin on Treating Type 2 Diabetic Patients with Early Diabetic Kidney Disease
Feng Qiwen,Li Xiaoyong,Chen Hanbei
DOI: https://doi.org/10.3760/cma.j.issn.1008-6315.2016.11.001
2016-01-01
Abstract:Objective To assess the clinical effect of Linagliptin on treating type 2 diabetic patients with early diabetic kidney disease. Methods Fifty cases type 2 diabetes patients with early diabetic kidney dis?ease were selected and randomly divided into two groups. All patients carried out diabetes education,strict diet therapy,and proper exercise. Twenty?six cases patients were enrolled in Linagliptin group,oral Linagliptin 5 mg, 1 times/d. Twenty?four cases patients were enrolled in Gliclazide group,oral Gliclazide 30 mg,1 times/d,and monitored the blood sugar to adjust drug dosage,the maximum dose of 60 mg,1 times/d. The observation time of both groups was six months. The glycosylated hemoglobin ( HbA1c ) and urinary albumin?to?creatinine ratio ( UACR) of two groups were compared before and after treatment. Results The level of HbA1c in Linagliptin group after treatment was lower than before treatment,the difference was significant((7. 39±0. 37)% vs. (8. 30 ±0. 48)%,t=14. 232,P<0. 001). The level of HbA1c in Gliclazide group after treatment was lower than before treatment,the difference was significant((7. 45±0. 41)% vs. (8. 38±0. 49)%,t=23. 146,P<0. 001). There was no significant difference on the level of HbA1c between the two groups after treatment ( t=-0. 517, P=0. 608) . The level of UACR in Linagliptin group after treatment was lower than before treatment,the difference was significant((83. 64±37. 44) mg/g vs. (109. 56±53. 36) mg/g,t=4. 632,P<0. 001). The level of UACR in Gliclazide group after treatment was lower than before treatment,the difference was significant((93. 58±47. 17) mg/g vs. (103. 77±48. 80) mg/g,t=2. 909,P=0. 008). There was significant difference on the level of UACR between the two groups after treatment( t=-2. 172,P=0. 035) . Conclusion Linagliptin is a kind of effective and safe regent,can be used in patients with type 2 diabetes and early diabetic kidney disease.